Insulet Shares Plunge 20% on Lowered Omnipod Sales Guidance Despite Q2 Revenue Beat
Insulet Corp. reported better-than-expected Q2 revenue of $801.7M but cut its full-year 2026 Omnipod sales growth forecast to 17%-19%, sending shares down 20.1%.
What happened
Insulet Corp. (NASDAQ: PODD), a medical device company that manufactures the Omnipod insulin pump, reported second-quarter 2026 results on August 5. Revenue of $801.7 million rose 23.5% year over year and beat analyst estimates, according to the company's press release. However, management lowered its fiscal 2026 revenue growth guidance for the Omnipod product line, particularly in the U.S., to 17%–19%, down from previous expectations. The guidance cut triggered a sharp sell-off: the stock closed at $133.26, down 20.1% from the prior day's $166.82, on volume of 7.1 million shares, nearly five times the average.
The numbers
Insulet reported Q2 2026 revenue of $801.7 million, a year-over-year increase of 23.5%, and above consensus estimates, according to the company's investor relations page. The prior-year quarter revenue was $649 million. The company did not disclose net income or earnings per share in the verified sources provided.
Outlook
Insulet lowered its full-year 2026 revenue growth guidance for the Omnipod platform. Multiple media outlets, including Investors.com, Benzinga, Seeking Alpha, and Yahoo Finance, reported that the company now expects Omnipod revenue growth of 17% to 19%, citing the company's earnings call. The sources do not explain why the growth rate was reduced; Insulet's own press release did not provide a specific reason.
Sources
- Daily price and volume history
- Investors.com, Benzinga, Seeking Alpha, Yahoo Finance
- Insulet Corporation press release (investor.insulet.com)
Information summarized by AI from the sources listed above. May contain errors — informational only, not investment advice.